Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Interest Expenses (2016 - 2024)

Historic Interest Expenses for Sunshine Biopharma (SBFM) over the last 11 years, with Q4 2024 value amounting to $8529.0.

  • Sunshine Biopharma's Interest Expenses fell 7167.39% to $8529.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $8529.0, marking a year-over-year decrease of 8927.66%. This contributed to the annual value of $8774.0 for FY2024, which is 9361.0% down from last year.
  • As of Q4 2024, Sunshine Biopharma's Interest Expenses stood at $8529.0, which was down 7167.39% from $245.0 recorded in Q2 2024.
  • Sunshine Biopharma's Interest Expenses' 5-year high stood at $195630.0 during Q2 2021, with a 5-year trough of $2.0 in Q3 2022.
  • For the 5-year period, Sunshine Biopharma's Interest Expenses averaged around $39296.4, with its median value being $28328.0 (2022).
  • In the last 5 years, Sunshine Biopharma's Interest Expenses crashed by 9999.57% in 2022 and then soared by 192625000.0% in 2023.
  • Sunshine Biopharma's Interest Expenses (Quarter) stood at $105436.0 in 2020, then tumbled by 65.26% to $36630.0 in 2021, then dropped by 27.53% to $26546.0 in 2022, then grew by 13.43% to $30110.0 in 2023, then tumbled by 71.67% to $8529.0 in 2024.
  • Its last three reported values are $8529.0 in Q4 2024, $245.0 for Q2 2024, and $49181.0 during Q1 2024.